Literature DB >> 22961865

Selective V(1a) agonism attenuates vascular dysfunction and fluid accumulation in ovine severe sepsis.

Sebastian Rehberg1, Yusuke Yamamoto, Linda Sousse, Eva Bartha, Collette Jonkam, Anthony K Hasselbach, Lillian D Traber, Robert A Cox, Martin Westphal, Perenlei Enkhbaatar, Daniel L Traber.   

Abstract

Vasopressin analogs are used as a supplement to norepinephrine in septic shock. The isolated effects of vasopressin agonists on sepsis-induced vascular dysfunction, however, remain controversial. Because V(2)-receptor stimulation induces vasodilation and procoagulant effects, a higher V(1a)- versus V(2)-receptor selectivity might be advantageous. We therefore hypothesized that a sole, titrated infusion of the selective V(1a)-agonist Phe(2)-Orn(8)-Vasotocin (POV) is more effective than the mixed V(1a)-/V(2)-agonist AVP for the treatment of vascular and cardiopulmonary dysfunction in methicillin resistant staphylococcus aureus pneumonia-induced, ovine sepsis. After the onset of hemodynamic instability, awake, chronically instrumented, mechanically ventilated, and fluid resuscitated sheep were randomly assigned to receive continuous infusions of either POV, AVP, or saline solution (control; each n = 6). AVP and POV were titrated to maintain mean arterial pressure above baseline - 10 mmHg. When compared with that of control animals, AVP and POV reduced neutrophil migration (myeloperoxidase activity, alveolar neutrophils) and plasma levels of nitric oxide, resulting in higher mean arterial pressures and a reduced vascular leakage (net fluid balance, chest and abdominal fluid, pulmonary bloodless wet-to-dry-weight ratio, alveolar and septal edema). Notably, POV stabilized hemodynamics at lower doses than AVP. In addition, POV, but not AVP, reduced myocardial and pulmonary tissue concentrations of 3-nitrotyrosine, VEGF, and angiopoietin-2, thereby leading to an abolishment of cumulative fluid accumulation (POV, 9 ± 15 ml/kg vs. AVP, 110 ± 13 ml/kg vs. control, 213 ± 16 ml/kg; P < 0.001 each) and an attenuated cardiopulmonary dysfunction (left ventricular stroke work index, PaO(2)-to-FiO(2) ratio) versus control animals. Highly selective V(1a)-agonism appears to be superior to unselective vasopressin analogs for the treatment of sepsis-induced vascular dysfunction.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22961865      PMCID: PMC3517638          DOI: 10.1152/ajpheart.00390.2012

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  52 in total

Review 1.  The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination.

Authors:  G R Bernard; A Artigas; K L Brigham; J Carlet; K Falke; L Hudson; M Lamy; J R Legall; A Morris; R Spragg
Journal:  Am J Respir Crit Care Med       Date:  1994-03       Impact factor: 21.405

Review 2.  Endothelial activation, dysfunction and permeability during severe infections.

Authors:  Warren L Lee; W Conrad Liles
Journal:  Curr Opin Hematol       Date:  2011-05       Impact factor: 3.284

3.  Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-Kinase/Akt signal transduction pathway.

Authors:  I Kim; H G Kim; J N So; J H Kim; H J Kwak; G Y Koh
Journal:  Circ Res       Date:  2000 Jan 7-21       Impact factor: 17.367

Review 4.  Vasopressin for treatment of vasodilatory shock: an ESICM systematic review and meta-analysis.

Authors:  Angelo Polito; Emilio Parisini; Zaccaria Ricci; Sergio Picardo; Djillali Annane
Journal:  Intensive Care Med       Date:  2011-11-30       Impact factor: 17.440

5.  Dopexamine reverses the vasopressin-associated impairment in tissue oxygen supply but decreases systemic blood pressure in ovine endotoxemia.

Authors:  Martin Westphal; Andreas Wilhelm Sielenkämper; Hugo Van Aken; Henning Dirk Stubbe; Fritz Daudel; Ralf Schepers; Simone Schulte; Hans-Georg Bone
Journal:  Anesth Analg       Date:  2004-09       Impact factor: 5.108

6.  Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.

Authors:  R Phillip Dellinger; Mitchell M Levy; Jean M Carlet; Julian Bion; Margaret M Parker; Roman Jaeschke; Konrad Reinhart; Derek C Angus; Christian Brun-Buisson; Richard Beale; Thierry Calandra; Jean-Francois Dhainaut; Herwig Gerlach; Maurene Harvey; John J Marini; John Marshall; Marco Ranieri; Graham Ramsay; Jonathan Sevransky; B Taylor Thompson; Sean Townsend; Jeffrey S Vender; Janice L Zimmerman; Jean-Louis Vincent
Journal:  Crit Care Med       Date:  2008-01       Impact factor: 7.598

7.  Comparison of cardiac, hepatic, and renal effects of arginine vasopressin and noradrenaline during porcine fecal peritonitis: a randomized controlled trial.

Authors:  Florian Simon; Ricardo Giudici; Angelika Scheuerle; Michael Gröger; Pierre Asfar; Josef A Vogt; Ulrich Wachter; Franz Ploner; Michael Georgieff; Peter Möller; Régent Laporte; Peter Radermacher; Enrico Calzia; Balázs Hauser
Journal:  Crit Care       Date:  2009-07-10       Impact factor: 9.097

8.  Potential role of poly(adenosine 5'-diphosphate-ribose) polymerase activation in the pathogenesis of myocardial contractile dysfunction associated with human septic shock.

Authors:  Francisco G Soriano; Antonio C Nogueira; Elia G Caldini; Marcelo H Lins; Ana C Teixeira; Sylas B Cappi; Paulo A Lotufo; Márcia M S Bernik; Zsuzsanna Zsengellér; Min Chen; Csaba Szabó
Journal:  Crit Care Med       Date:  2006-04       Impact factor: 7.598

9.  Vasopressin versus norepinephrine infusion in patients with septic shock.

Authors:  James A Russell; Keith R Walley; Joel Singer; Anthony C Gordon; Paul C Hébert; D James Cooper; Cheryl L Holmes; Sangeeta Mehta; John T Granton; Michelle M Storms; Deborah J Cook; Jeffrey J Presneill; Dieter Ayers
Journal:  N Engl J Med       Date:  2008-02-28       Impact factor: 91.245

Review 10.  Microvascular dysfunction as a cause of organ dysfunction in severe sepsis.

Authors:  Jean-Louis Vincent; Daniel De Backer
Journal:  Crit Care       Date:  2005-08-25       Impact factor: 9.097

View more
  11 in total

Review 1.  Fluid resuscitation in sepsis: the great 30 mL per kg hoax.

Authors:  Paul E Marik; Liam Byrne; Frank van Haren
Journal:  J Thorac Dis       Date:  2020-02       Impact factor: 2.895

2.  The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis*.

Authors:  Marc O Maybauer; Dirk M Maybauer; Perenlei Enkhbaatar; Régent Laporte; Halina Wiśniewska; Lillian D Traber; ChiiDean Lin; Juanjuan Fan; Hal K Hawkins; Robert A Cox; Kazimierz Wiśniewski; Claudio D Schteingart; Donald W Landry; Pierre J-M Rivière; Daniel L Traber
Journal:  Crit Care Med       Date:  2014-07       Impact factor: 7.598

3.  Arginine vasopressin receptor 2 activation promotes microvascular permeability in sepsis.

Authors:  Ernesto Lopez; Satoshi Fukuda; Katalin Modis; Osamu Fujiwara; Baigal Enkhtaivan; Raul Trujillo-Abarca; Koji Ihara; Francisco Lima-Lopez; Dannelys Perez-Bello; Csaba Szabo; Donald S Prough; Perenlei Enkhbaatar
Journal:  Pharmacol Res       Date:  2020-11-04       Impact factor: 7.658

4.  Safety and Efficacy of Vasopressin After Fontan Completion: A Randomized Pilot Study.

Authors:  Amee M Bigelow; Nancy S Ghanayem; Nathan E Thompson; John P Scott; Laura D Cassidy; Katherine J Woods; Ronald K Woods; Michael E Mitchell; Viktor Hraŝka; George M Hoffman
Journal:  Ann Thorac Surg       Date:  2019-08-07       Impact factor: 5.102

5.  HMGB1 as a drug target in staphylococcal pneumonia.

Authors:  Mitchell P Fink
Journal:  Crit Care       Date:  2014-03-31       Impact factor: 9.097

Review 6.  Iatrogenic salt water drowning and the hazards of a high central venous pressure.

Authors:  Paul E Marik
Journal:  Ann Intensive Care       Date:  2014-06-21       Impact factor: 6.925

7.  Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients.

Authors:  James A Russell; Jean-Louis Vincent; Anne Louise Kjølbye; Håkan Olsson; Allan Blemings; Herbert Spapen; Peder Carl; Pierre-Francois Laterre; Lars Grundemar
Journal:  Crit Care       Date:  2017-08-15       Impact factor: 9.097

Review 8.  Shock - Classification and Pathophysiological Principles of Therapeutics.

Authors:  Olga N Kislitsina; Jonathan D Rich; Jane E Wilcox; Duc T Pham; Andrei Churyla; Esther B Vorovich; Kambiz Ghafourian; Clyde W Yancy
Journal:  Curr Cardiol Rev       Date:  2019

9.  A Selective V(1A) Receptor Agonist, Selepressin, Is Superior to Arginine Vasopressin and to Norepinephrine in Ovine Septic Shock.

Authors:  Xinrong He; Fuhong Su; Fabio Silvio Taccone; Régent Laporte; Anne Louise Kjølbye; Jing Zhang; Keliang Xie; Mouhamed Djahoum Moussa; Torsten Michael Reinheimer; Jean-Louis Vincent
Journal:  Crit Care Med       Date:  2016-01       Impact factor: 7.598

Review 10.  New Agents in Development for Sepsis: Any Reason for Hope?

Authors:  Philippe Vignon; Pierre-François Laterre; Thomas Daix; Bruno François
Journal:  Drugs       Date:  2020-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.